SOLSTICE BIOLOGICS LTD has a total of 26 patent applications. It decreased the IP activity by 16.0%. Its first patent ever was published in 2014. It filed its patents most often in EPO (European Patent Office), Canada and Australia. Its main competitors in its focus markets organic fine chemistry, pharmaceuticals and biotechnology are AKIRA KAJI, ROCHE INNOVATION CENTER COPENHAGEN A and BONAC CORP.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | Canada | 5 | |
#3 | Australia | 4 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | China | 3 | |
#6 | United States | 3 | |
#7 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals | |
#3 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Sugars | |
#2 | Microorganisms | |
#3 | Therapeutic chemical compounds | |
#4 | Medical preparations | |
#5 | Special acyclic compounds | |
#6 | Peptides | |
#7 | Organic chemistry methods |
# | Name | Total Patents |
---|---|---|
#1 | Sakamuri Sukumar | 26 |
#2 | Bradshaw Curt W | 24 |
#3 | Eltepu Laxman | 23 |
#4 | Lam Son | 21 |
#5 | Liu Dingguo | 19 |
#6 | Meade Bryan R | 16 |
#7 | Liu Bin | 15 |
#8 | Stock Joseph | 11 |
#9 | Iacono Giuseppe Dello | 9 |
#10 | Kabakibi Ayman | 7 |
Publication | Filing date | Title |
---|---|---|
EP3645546A1 | Chiral phosphoramidite auxiliaries and methods of their use | |
CN110770345A | Immunomodulatory polynucleotides, antibody conjugates, and methods of use thereof | |
KR20190058477A | Polynucleotide construct | |
WO2017100461A1 | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate | |
CA2969733A1 | Mononucleotides having a bioreversible disulfide group | |
CA2950960A1 | Polynucleotide constructs having bioreversible and non-bioreversible groups | |
AU2014346658A1 | Polynucleotide constructs having disulfide groups |